Disc Medicine

Disc Medicine

Disc Medicine

We are restoring regulation of hepcidin the link between genetics and erythropoiesis to create new therapies for patients with inherited and acquired anemias.
Type
B2c
Raised
$90M
Follow us
Alexa global traffic share
Latest funding
$90,000,000
Venture capital (Series B) - 2021
Atlas Venture Rock Springs Capital OrbiMed +7
Team Size
1–10
Employees
$90,000,000 Venture capital (Series B)
MedCity News

Blood disorder biotech Disc Medicine gets $90M to bring two drugs into Phase 2